Neurizon Therapeutics Limited (ASX:NUZ)
Australia
· Delayed Price · Currency is AUD 0.0820
-0.0010 (-1.20%)
At close: Mar 6, 2026
Neurizon Therapeutics Company Description
Neurizon Therapeutics Limited, a clinical stage biotechnology company, develops therapeutics for neurodegenerative diseases.
The company develops drug discovery intellectual property for the treatment of neurological diseases.
Its lead candidate is NUZ-001, a small molecule drug which is in Phase II clinical trials for the treatment of amyotrophic lateral sclerosis, as well as to treat other neurodegenerative diseases.
The company was formerly known as PharmAust Limited and changed its name to Neurizon Therapeutics Limited in October 2024.
Neurizon Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.
Neurizon Therapeutics Limited
| Country | Australia |
| Founded | 2000 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 4 |
| CEO | Michael Thurn |
Contact Details
Address: Suite 2 Melbourne, VIC 3000 Australia | |
| Phone | 61 3 9692 7222 |
| Website | neurizon.com |
Stock Details
| Ticker Symbol | NUZ |
| Exchange | Australian Securities Exchange |
| Fiscal Year | July - June |
| Reporting Currency | AUD |
| ISIN Number | AU0000357261 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Michael Thurn Ph.D. | MD, Chief Executive Officer and Director |
| Dan O'Connell | Chief Financial Officer |
| John Clark | Chief Operating Officer |
| Dr. Nicky Wallis | Chief Scientific Officer |
| Lidija Damjanovic | Head of Marketing and Corporate Affairs |
| Dr. Gary Pitt | Head of Chemistry |
| Dr. James Rixson | Head of Production |
| Dr. Herbert Brinkman | Head of Manufacturing |
| Dr. Chris Freitag M.D. | Chief Medical Advisor |
| Dr. Jeffrey M. Brown M.B.A., Ph.D. | Chief Scientific Advisor |